

DOCKET NO.: CSKL0003-100**PATENT****In the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 26, 29, 34, and 35 as follows.

1-25. (cancelled).

26. (currently amended) A method of inhibiting cell division comprising contacting a cell with an effective amount of 3-iodoacetamido benzoyl ethyl ester (3-IAABE), wherein the cell is selected from a leukemia ~~cancer~~ cell, a melanoma ~~cancer~~ cell, a renal cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a colon cancer cell, a prostate cancer cell, and a lymphoma ~~cancer~~ cell.

27. (previously presented) The method of claim 26 wherein the cell is contacted with 0.005 to 0.51 $\mu\text{g/ml}$ of 3-IAABE.

28. (previously presented) The method of claim 26 wherein the cell is a prostate cancer cell.

29. (currently amended) The method of claim 26 wherein the cancer cell is a lymphoma ~~cancer~~ cell.

30. (previously presented) The method of claim 26 wherein the cell is a colon cancer cell.

31. (previously presented) The method of claim 26 wherein the cell is a non-small cell lung cancer cell.

32. (previously presented) The method of claim 26 wherein the cell is a breast cancer cell.

33. (previously presented) The method of claim 26 wherein the cell is a renal cancer cell.

DOCKET NO.: CSKL0003-100**PATENT**

34. (currently amended) The method of claim 26 wherein the cell is a melanoma ~~cancer~~ cell.
35. (currently amended) The method of claim 26 wherein the cell is a leukemia ~~cancer~~ cell.